Unicycive Therapeutics, Inc.
UNCY
$6.93
-$0.19-2.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 68.40% | 89.81% | 90.26% | 70.79% | 41.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.10% | 8.18% | 5.57% | 19.88% | 49.73% |
| Operating Income | 8.10% | -8.18% | -5.57% | -19.88% | -54.60% |
| Income Before Tax | 27.70% | -45.26% | -35.54% | 58.85% | -20.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.70% | -45.26% | -35.54% | 58.85% | -20.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.70% | -45.26% | -35.54% | 58.85% | -20.25% |
| EBIT | 8.10% | -8.18% | -5.57% | -19.88% | -54.60% |
| EBITDA | 8.14% | -8.14% | -5.53% | -19.87% | -54.56% |
| EPS Basic | 76.37% | 56.42% | 59.92% | 110.34% | 60.88% |
| Normalized Basic EPS | 74.73% | 53.44% | 57.40% | 101.25% | 62.26% |
| EPS Diluted | 82.58% | 71.54% | 72.52% | 68.73% | 27.59% |
| Normalized Diluted EPS | 79.95% | 62.83% | 65.12% | 88.40% | 52.35% |
| Average Basic Shares Outstanding | 137.35% | 167.66% | 209.73% | 197.09% | 173.04% |
| Average Diluted Shares Outstanding | 98.34% | 110.98% | 124.78% | 250.79% | 230.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 1.00% | 1.00% | -- | -- |